Embecta shares plummeted 61.5% following a disappointing quarter marked by a sharp revenue decline and a significant guidance cut driven primarily by share losses and volume softness in its core pen needle category.

• Q2 revenues dropped 14.4% year-over-year on an as-reported basis and 17.4% on an adjusted constant currency basis, missing expectations.
• U.S. revenue shortfall dominated by approximately $25 million in market share loss and $20 million from overall market volume weakness in pen needles.
• Additional $8 million in pen needle revenue headwinds from inventory reduction and pricing pressure; syringe sales also down by $13 million, largely due to reduced use of compounded drugs.
• Alcohol swab product discontinuation contributed approximately $5 million to the revenue decline, following supplier issues.
• Full-year 2026 revenue guidance slashed from $1.071–1.093 billion to $1.015–1.035 billion, reflecting ongoing U.S. challenges despite steady international performance.